Prostate Cancer Clinical Trial
— SHOR-TESTOfficial title:
The Effect of Exercise on Tumor Hypoxia in Men With Localized Prostate Cancer Undergoing Radical Prostatectomy - a Randomized Controlled Pilot Study
Verified date | December 2019 |
Source | Rigshospitalet, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background and purpose: The purpose of this study is to investigate the effect of one acute
exercise bout on tumor hypoxia in patients with localized prostate cancer undergoing radical
prostatectomy.
The primary hypothesis is that exercise reduces tumor hypoxia and that the reduction is
greater in patients performing one acute high intensity exercise bout compared to no training
controls.
The investigators have not been able to identify any prior or current randomized trials
investigating exercise and tumor hypoxia, and believe that such research is warranted and
would be of great importance. Moreover there is a need for studies including biological
measurements to allow a full assessment of the effect of exercise on diverse biomarkers and
mechanistic pathways, which may influence cancer survival.
Subjects: Patients with histologically verified prostate adenocarcinoma scheduled for radical
prostatectomy at Urologic Department, Rigshospitalet, Copenhagen, Denmark.
Methods: In this randomized controlled pilot study 30 patients with localized prostate cancer
undergoing radical prostatectomy will be included and randomized 2:1 to either one single
acute High Intensity Interval Training bout or usual care and no training the day prior to
radical prostatectomy.
All patients will undergo assessment at inclusion (baseline) and the day prior to surgery.
Assessment includes: anthropometrics; blood pressure; resting hearth rate; hip and waist
circumference, ECG, quality of life by self-report questionnaires; fasting blood sample
measuring PSA (prostate specific antigen), cholesterol, triglycerides, insulin, c-peptide,
HbA1c, glucose and inflammatory markers.
All patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface)
in order to quantify tumor hypoxia by pathological analyses after removal of the prostate.
Biological tissue from tumor (primary prostate biopsies) will also be retrieved from the
respective local pathological departments and from the perioperative prostate specimen and
sent to protocol analyses.
Status | Completed |
Enrollment | 30 |
Est. completion date | November 24, 2019 |
Est. primary completion date | November 24, 2019 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Men with histologically verified localized prostate adenocarcinoma undergoing curative intended radical prostatectomy. Exclusion Criteria: - Age: <18 years - Any other known malignancy requiring active treatment - Performance status > 1 - Allergy to pimonidazole - Ongoing treatment with beta blockers - Physical disabilities precluding physical testing and/or exercise - Inability to read and understand Danish |
Country | Name | City | State |
---|---|---|---|
Denmark | Center for Physical Activity Research, Copenhagen University Hospital | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tumor hypoxia | Quantification of tumor hypoxia will be assessed using pimonidazole staining | At prostatectomy | |
Secondary | Intratumoral immune cell infiltration | Intratumoral immune cell infiltration will be quantified using histological analyses | Primary prostate biopsies and until radical prostatectomy | |
Secondary | Tumor vessel morphology | Tumor vessel morphology will be evaluated using histological analyses | Primary prostate biopsies and until radical prostatectomy | |
Secondary | Tumor metabolism-, biology and signaling | Tumor samples will undergo proteomic analyses in order to uncover potential upregulated biomarkers | Primary prostate biopsies and until radical prostatectomy | |
Secondary | Changes in immune cells during an acute exercise bout | Changes in immune cells during an acute exercise bout will be measured in blood samples using flowcytometry | From start of exercise bout and until 60 minutes post exercise | |
Secondary | Changes in epinephrine concentration | Concentration of epinephrine will be measured in blood samples by radioimmunoassay analyses. | From start of exercise bout and until 60 minutes post exercise | |
Secondary | Changes in nor-epinephrine concentration | Concentration of nor-epinephrine will be measured in blood samples by radioimmunoassay analyses. | From start of exercise bout and until 60 minutes post exercise | |
Secondary | Changes in various interleukines | Concentration of various interleukines will be measured in blood samples by measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses. | From start of exercise bout and until 60 minutes post exercise | |
Secondary | Changes in Tumor Necrosis Factor alpha (TNFa) concentration | Concentrations of TNFa will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses. | From start of exercise bout and until 60 minutes post exercise | |
Secondary | Changes in Interferon Gamma (IFN?) concentration | Concentrations of IFN? will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses. | From start of exercise bout and until 60 minutes post exercise | |
Secondary | Concentration of C-reactive Protein (CRP) | Concentration of CRP will be measured in fasting blood sample by standard laboratory methods. | Blood sampling on the day of radical prostatectomy | |
Secondary | Total plasma cholesterol concentration | Concentrations of total cholesterol will be measured in fasting blood samples by standard laboratory methods. | Blood sampling on the day of radical prostatectomy | |
Secondary | Plasma LDL-Cholesterol concentration | Concentrations of LDL- cholesterol will be measured in fasting blood samples by standard laboratory methods. | Blood sampling on the day of radical prostatectomy | |
Secondary | Plasma HDL-Cholesterol concentration | Concentrations of HDL- cholesterol will be measured in fasting blood samples by standard laboratory methods. | Blood sampling on the day of radical prostatectomy | |
Secondary | Plasma triglyceride concentrations | Concentrations of triglycerides will be measured in fasting blood samples by standard laboratory methods. | Blood sampling on the day of radical prostatectomy | |
Secondary | HbA1C concentration | Concentrations of HbA1C will be measured in fasting blood samples by standard laboratory methods. | Blood sampling on the day of radical prostatectomy | |
Secondary | Plasma Insulin concentration | Concentrations of insulin will be measured in fasting blood samples by standard laboratory methods. | Blood sampling on the day of radical prostatectomy | |
Secondary | Plasma Glucose concentration | Concentrations of glucose will be measured in fasting blood samples by standard laboratory methods. | Blood sampling on the day of radical prostatectomy | |
Secondary | Wattmax-test | The participants in the HIIT group will undergo a maximal graded exercise test on a bicycle ergometer for evaluation of cardiovascular function and determination of the maximum watt (wattmax). The test starts with a 3 min warm up at 70 watt (the watts may have to be adjusted to the individual fitness level). Warm up is immediately followed by a 20 watt increase every 1 min until exhaustion. The maximum watt will be calculated. | At baseline assessment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |